<DOC>
	<DOCNO>NCT00510068</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival participant assign everolimus 10 mg/day plus Best Supportive Care versus assign placebo plus Best Supportive Care Advanced Neuroendocrine Tumors pancreatic origin .</brief_summary>
	<brief_title>Efficacy Safety Everolimus ( RAD001 ) Compared Placebo Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must advance ( unresectable metastatic ) biopsyproven pancreatic NET 2 . Measurable disease radiologic assessment 3 . Adequate blood work 4 . Performance Status 02 : Ability bed time 5 . Adult male female patient â‰¥ 18 year age 6 . Women childbearing potential must negative serum pregnancy test 7 . Written informed consent patient must obtain accordance local guideline Exclusion criterion : 1 . Patients severe kind ( poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid small cell carcinoma ) cancer eligible 2 . Other chemotherapy , immunotherapy radiotherapy within 4 week prior start trial 3 . Hepatic artery procedure call embolization within last 6 month ( 1 month site measurable disease ) , cryoablation/ radiofrequency ablation hepatic metastasis within 2 month enrollment 4 . Prior therapy kind medication ( mTOR inhibitor : sirolimus , temsirolimus , everolimus ) . 5 . Uncontrolled diabetes mellitus Patients severe and/or uncontrolled medical condition : 6 . Patients receive chronic treatment corticosteroid another immunosuppressive agent 7 . Patients known history HIV seropositivity 8 . No prior concurrent cancer time enrol trial Other protocol define inclusion/ exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Advanced Neuroendocrine Tumor adult</keyword>
	<keyword>RAD001</keyword>
	<keyword>NET</keyword>
	<keyword>everolimus</keyword>
	<keyword>mTOr</keyword>
	<keyword>islet cell</keyword>
	<keyword>neuroendocrine</keyword>
</DOC>